Impact Factor
3.25
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.36
554 total citations
h5-index
25
h5 depth signal
Cited share
71.5%
176 of 246
Total citations
554
Citation footprint
Metric signal
2.04
External metric anchor
Self-citation
7.4%
41 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
200
Netherlands
192
France
155
Japan
145
China
122
Citing Fields of Research
Pharmacology & Toxicology
253
Antibiotic & Antibacterial Agents
228
Transplantation
198
Clinical Laboratory Science
188
Brain Neurological Disorders
123
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
6,602
Articles tracked across the journal lifetime
Indexed publication set
246
176 cited publications
Last 12 months
125
10.4 publications/month
Open access share
20.8%
26 OA publications in the last year
Leading citing country
United States
200 citing publications
Leading citing field
Pharmacology & Toxicology
253 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1979-
v1n1, 1979-
Active Coverage
Research Focus & Classification
Indexed Subjects
Antibiotic & Antibacterial Agents
Transplantation
Pharmacology & Toxicology
Clinical Laboratory Science
Psychiatry
Brain Neurological Disorders
Broad Categories
Drug Therapy
Antibiotic & Antibacterial Agents
Transplantation
Brain Neurological Disorders
Psychiatry
Hematology
Substance Abuse
MeSH Descriptors
Drug Therapy
Monitoring, Physiologic
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/ftd.0000000000001534
Open DOI
Integrating Artificial Intelligence and Multicenter Real-World Evidence to Advance Precision Dosing: A Critical Perspective Review
Background: Precision dosing integrates patient-specific factors to optimize pharmacotherapy. However, current evidence often relies on limited single-center studies, restricting generalizability. Methods: A narrative review of literatur...
02
DOI 10.1097/ftd.0000000000001523
Open DOI
Effect of Vasopressin Infusion Rate on Vancomycin Dose Adjustment in Pediatric Central Diabetes Insipidus: Grand Round/A Case Study
Background: Vancomycin (VCM)-associated acute kidney injury is a clinically important adverse event. Appropriate dose adjustment requires knowledge of factors influencing VCM clearance; however, these factors remain poorly characterized ...
03
DOI 10.1097/ftd.0000000000001533
Open DOI
Measurement of Tamoxifen and Endoxifen Concentrations via Liquid Chromatography-Tandem Mass Spectrometry to Assess Adherence and Optimal Concentrations in South Africans with Breast Cancer Participating in a Pilot Trial: A Short Communication
Background: Breast cancer is a leading cause of cancer-related mortality in women globally. Breast cancer patients treated with tamoxifen demonstrate interpatient variability, with adherence challenges affecting up to 50% of patients by ...
04
DOI 10.1097/ftd.0000000000001524
Open DOI
Development and Validation of a Chlorothiazide Whole-Blood Microsampling Assay
Background: Chlorothiazide (CLTZ) is among the most commonly prescribed diuretics for preterm infants with bronchopulmonary dysplasia, yet no contemporary pharmacokinetic (PK) data inform its dosing in this population. Traditional plasma...
05
DOI 10.1097/ftd.0000000000001536
Open DOI
Gender-Based Differences in the Effects of Valproate on Dose-Corrected Plasma Concentrations of Quetiapine and Its Metabolites: A Retrospective Cohort Study
Background: This retrospective study aimed to investigate the effects of valproate on the concentration-to-dose (C/D) ratio of quetiapine and N-desalkylquetiapine. Methods: Multiple linear regression analysis was used to identify indepen...
06
DOI 10.1097/ftd.0000000000001538
Open DOI
Dose-dependent Effects of Cenobamate on Brivaracetam Pharmacokinetics: A Retrospective Cohort Study
Background: Cenobamate is a novel antiseizure medication that inhibits cytochrome P450 2C19 (CYP2C19), which is involved in brivaracetam metabolism. Therefore, a pharmacokinetic interaction is assumed. In this study, the authors investig...
07
DOI 10.1097/ftd.0000000000001539
Open DOI
Therapeutic Drug Monitoring of Antifungal Agents: Toward Harmonization of Therapeutic Ranges
Background: Invasive fungal infections are associated with high morbidity and mortality, particularly among immunocompromised and critically ill patients. Antifungal therapy is complicated by substantial pharmacokinetic variability, drug...
08
DOI 10.1097/ftd.0000000000001530
Open DOI
Intertwin Amikacin Exposure in Conjoined Twins: A Therapeutic Drug Monitoring–Informed Coupled Pharmacokinetic Modeling Case Study
Background: Conjoined twins represent a rare condition in which drug exposure may be influenced by shared circulation and organ anatomy. For narrow therapeutic index antimicrobials such as amikacin, therapeutic drug monitoring (TDM) may ...
09
DOI 10.1097/ftd.0000000000001522
Open DOI
Determination of the Presence of Daridorexant, a New Hypnotic, in Hair After a Single Exposure and Application to Repetitive Exposures
Background: Daridorexant, a new hypnotic used to treat chronic insomnia in adults, has been marketed in France since March 2024. It is an orexin receptor antagonist that blocks orexin binding and promotes sleep without disrupting the nat...
10
DOI 10.1097/ftd.0000000000001525
Open DOI
Impact of Hepatic Dysfunction on Vancomycin Area Under the Concentration–Time Curve Estimation and the Need for Early Therapeutic Drug Monitoring
Background: Renal function may be overestimated in patients with hepatic dysfunction because of reduced creatinine production; however, its impact on the vancomycin dosing regimen is unclear. In this study, the characteristics of steady-...
Bibliographical & Catalog Notes
Place of publication varies.
Also issued online.
Vol. 11, no. 1 (JAN 1989)19900914 Notice not published Printed on acid-free paper